RF for Emerging Applications Medical RF Applications Informational

How does a microwave hyperthermia system work for cancer treatment and what frequencies are used?

A microwave hyperthermia system for cancer treatment uses focused microwave energy to heat tumors to 40-45 degrees C (hyperthermia range), which damages cancer cells (which are more temperature-sensitive than normal cells) and enhances the effectiveness of radiation therapy and chemotherapy. The system works by delivering microwave power from an external applicator (antenna array) through the body tissue to the tumor location, where the electromagnetic energy is absorbed and converted to heat. The frequencies used for microwave hyperthermia are: 433 MHz (ISM band, Europe; deepest penetration, approximately 5-7 cm effective heating depth in muscle, but lower spatial resolution), 915 MHz (ISM band, US; good balance of penetration approximately 3-4 cm and focusing ability), and 2.45 GHz (ISM band, worldwide; best spatial focusing approximately 1-2 cm spot size, but limited penetration depth approximately 1.5-2 cm, best for superficial tumors). The choice of frequency depends on the tumor depth: deep tumors (>3 cm) require lower frequencies (433 MHz or 915 MHz) for adequate penetration, while superficial tumors benefit from higher frequencies (2.45 GHz) that concentrate heating in a smaller volume. The system includes: a microwave power source (solid-state amplifier, 50-150 W per channel), a phased array applicator (4-16 antennas surrounding the treatment volume), phase and amplitude control for each channel (to steer and focus the heating pattern), and temperature monitoring (fiber-optic temperature probes inserted near the tumor, or MRI thermometry for non-invasive 3D temperature mapping).

Category: RF for Emerging Applications

Updated: April 2026

Product Tie-In: Antennas, Low Power Transceivers, Filters

Microwave Hyperthermia Systems for Oncology

Microwave hyperthermia is used as an adjunct therapy (combined with radiation or chemotherapy) for various cancers including breast, cervical, head and neck, bladder, and melanoma. Clinical trials have shown 20-30% improvement in tumor control rates when hyperthermia is added to radiation therapy.

System Architecture

Power source: Solid-state power amplifiers (GaN or LDMOS) provide 50-150 W per channel. Multi-channel systems (4-16 channels) enable phased-array beamforming to focus heat at the tumor location. Total system power: 200-1000 W
Applicator array: Circular or planar array of waveguide, patch, or dipole antennas positioned around the treatment area. A coupling medium (water bolus) between the antennas and the body surface provides impedance matching and surface cooling
Phase/amplitude control: Each channel has independent phase (0-360 degrees) and amplitude (0-100%) control. The phases are set to constructively interfere at the tumor location, creating a focused heating spot (SAR focus). Phase optimization is performed using electromagnetic simulation or real-time feedback
Temperature monitoring: Invasive: fiber-optic temperature sensors (minimally invasive, 0.5 mm diameter) inserted through catheters near the tumor provide real-time temperature measurement. Non-invasive: MRI-guided hyperthermia uses proton resonance frequency shift (PRFS) thermometry to map the 3D temperature distribution throughout the treatment volume in real time

Hyperthermia Treatment Parameters

Penetration depth (half-power): d = lambda / (4 pi) x sqrt(2 / (Er (sqrt(1+tan_d^2)-1)))
At 915 MHz in muscle: d ~ 3-4 cm
At 2.45 GHz in muscle: d ~ 1.5-2 cm
SAR: P_absorbed = sigma |E|^2 / (2 rho) [W/kg]
Heating rate: dT/dt = SAR / c_tissue [C/sec, initial heating]

Common Questions

Frequently Asked Questions

How does hyperthermia kill cancer cells?

Hyperthermia at 40-45 degrees C damages cancer cells through several mechanisms: protein denaturation (disrupting cellular enzymes and structural proteins), increased membrane permeability (causing ion imbalance), impaired DNA repair (preventing cells from fixing radiation damage), and enhanced blood flow (improving drug delivery and oxygenation). Cancer cells are more susceptible to heat damage than normal cells because tumors have poor blood supply (disorganized vasculature), limiting their ability to dissipate heat and maintain homeostasis.

Is hyperthermia the same as thermal ablation?

No. Hyperthermia heats tissue to 40-45 degrees C (sub-lethal), weakening the cancer cells and making them more susceptible to radiation or chemotherapy. The cells die from the combined treatment. Thermal ablation heats tissue to 60-100 degrees C (lethal), directly killing all cells in the heated volume through coagulative necrosis. Ablation is a standalone treatment; hyperthermia is always used in combination with other therapies.

What are the main engineering challenges?

Precise focusing (steering the SAR focus to the tumor while minimizing heating of surrounding normal tissue), patient-specific treatment planning (each patient's anatomy is different, requiring individualized phase/amplitude optimization), temperature monitoring (knowing the actual 3D temperature distribution during treatment is critical for safety and efficacy), and deep heating (for tumors deeper than 5 cm, the electromagnetic field attenuates significantly, making adequate heating challenging with external applicators at available frequencies).

Keep Reading